Abstract
Introduction: Surgical revascularization in patients with (CAD) and advanced left ventricular dysfunction has historically carried a high perioperative mortality and morbidity; however, with advances in surgical techniques and myocardial protection methods the safety of CABG surgery in those patients with poor ventricular function has been demonstrated. Those high risk patients are particularly in danger of inability to be weaned from the cardiopulmonary bypass after cardiac surgery; in those patients inotropic agents are used first, followed by the intra aortic balloon pump, if required. Objectives: The aim of the study is to assess the impact of Enoximone administration to poor cardiac function IHD patients undergoing CABG, on short term clinical outcomes. Methods: Between June 2006 and June 2011, 215 patients with ischemic heart disease with poor function i.e. ejection fraction below 30% undergoing coronary artery bypass surgery; operated upon them in Ain Shams University hospitals in Egypt. The study population was divided into two groups: • Group A consisted of 104 patients who received Enoximone (phosphodiesterase inhibitor type 3) immediately after crossclamp removal and continue till the end of the ITU stay. • Group B consisted of 111 patients who did not receive Enoximone. Exclusion criteria were hemodynamic instability, associated surgically significant valvular lesions and severe co-morbidities (renal and hepatic failure, cancer, autoimmune disease).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.